0 followers
Phase 1 trial of MV-CHIK involved 180 subjects (150 MV-CHIK, 30 placebo). Higher dose (5 × 10⁵ TCID50) outperformed lower dose. Mild side effects noted, no prolonged arthralgia. 💉✨ #idsky
A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults
Overview of attention for article published in Journal of Infectious Diseases, November 2025